Answers are grounded in this paper and cite their sources.
Contemporary use of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and angiotensin receptor-neprilysin inhibitors (ARNi) in patients with atrial fibrillation (AF) and heart failure (HF) has not been described.
No takes yet. Share an insight, caveat, or question.
Alonso et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: